Atlas Trials

Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Clinical trial NCT02715193 · COMPLETED

Trial details

NCT number
NCT02715193
Sponsor
REMD Biotherapeutics, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Type 1 Diabetes MellitusDiabetes
Start date
2016-03-01
Primary completion
2017-01-01
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.